PT110634A - Ivermectina amorfa e processo para a sua produção - Google Patents

Ivermectina amorfa e processo para a sua produção

Info

Publication number
PT110634A
PT110634A PT11063418A PT11063418A PT110634A PT 110634 A PT110634 A PT 110634A PT 11063418 A PT11063418 A PT 11063418A PT 11063418 A PT11063418 A PT 11063418A PT 110634 A PT110634 A PT 110634A
Authority
PT
Portugal
Prior art keywords
ivermectin
amorphous
amorphable
medical device
pharmaceutical formulation
Prior art date
Application number
PT11063418A
Other languages
English (en)
Other versions
PT110634B (pt
Inventor
Silva Sérgio
Original Assignee
Hovione Farm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Farm Sa filed Critical Hovione Farm Sa
Priority to PT110634A priority Critical patent/PT110634B/pt
Priority to KR1020207029772A priority patent/KR20200135417A/ko
Priority to BR112020019214-7A priority patent/BR112020019214A2/pt
Priority to CN201980020433.4A priority patent/CN111902416A/zh
Priority to CA3094448A priority patent/CA3094448A1/en
Priority to US16/980,489 priority patent/US20210023111A1/en
Priority to MX2020009669A priority patent/MX2020009669A/es
Priority to AU2019237276A priority patent/AU2019237276B2/en
Priority to RU2020134019A priority patent/RU2810145C2/ru
Priority to EP19714723.4A priority patent/EP3768683A1/en
Priority to PCT/GB2019/050760 priority patent/WO2019180417A1/en
Priority to JP2020550864A priority patent/JP2021518416A/ja
Publication of PT110634A publication Critical patent/PT110634A/pt
Priority to IL277227A priority patent/IL277227A/en
Publication of PT110634B publication Critical patent/PT110634B/pt
Priority to JP2024067506A priority patent/JP2024083612A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/122—Pulverisation by spraying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glanulating (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)

Abstract

É APRESENTADA IVERMECTINA AMORFA ISOLADA NA FORMA SÓLIDA , E ADEQUADAMENTE ISENTA DE QUAISQUER ADITIVOS OU DE UMA MATRIZ DE SUPORTE , TAL COMO UMA DISPERSÃO SÓLIDA. TAMBÉM É APRESENTADA UMA FORMULAÇÃO FARMACÊUTICA , PARA USO EM ANIMAIS INCLUINDO HUMANOS OU PARA USO VETERINÁRIO, COMPREENDENDO A IVERMECTINA AMORFA DA INVENÇÃO, E UM VEÍCULO FARMACEUTICAMENTE ACEITÁVEL. TAMBÉM É APRESENTADO UM DISPOSITIVO MÉDICO QUE INCORPORA IVERMECTINA AMORFA DE ACORDO COM A INVENÇÃO, OU UM DISPOSITIVO MÉDICO QUE INCORPORA UMA FORMULAÇÃO FARMACÊUTICA DE ACORDO COM A INVENÇÃO AQUI DESCRITA. UM MÉTODO DE PREPARAÇÃO DE IVERMECTINA AMORFA COMPREENDE OS PASSOS DE PREPARAÇÃO DE UMA SOLUÇÃO DE IVERMECTINA EM PELO MENOS UM SOL VENTE; REMOÇÃO DO SOL VENTE POR ALIMENTAÇÃO DA SOLUÇÃO A UM SECADOR POR ATOMIZAÇÃO E RECOL HA DAS PARTÍCULAS DE IVERMECTINA. A IVERMECTINA AMORFA TAL COMO AQUI DIVULGADA PODE SER UTILIZADA COMO UM MEDICAMENTO, EM PARTICULAR PARA TRATAR CONDIÇÕES TAIS COMO PATOLOGIAS CAUSADAS POR INFEÇÕES INTERNAS POR NEMÁTODOS INCLUINDO MAS NÃO LIMITADAS A ONCOCERCOSE (CEGUEIRA DOS RIOS), FILARÍASE (ELEFANTÍASE), ESTRONGILOIDOSE OU DEMODICOSE.
PT110634A 2018-03-19 2018-03-19 Ivermectina amorfa e processo para a sua produção PT110634B (pt)

Priority Applications (14)

Application Number Priority Date Filing Date Title
PT110634A PT110634B (pt) 2018-03-19 2018-03-19 Ivermectina amorfa e processo para a sua produção
AU2019237276A AU2019237276B2 (en) 2018-03-19 2019-03-19 A novel form of ivermectin and a process for making it
RU2020134019A RU2810145C2 (ru) 2018-03-19 2019-03-19 Новая форма ивермектина и способ ее получения
CN201980020433.4A CN111902416A (zh) 2018-03-19 2019-03-19 新的伊维菌素形式及其制备方法
CA3094448A CA3094448A1 (en) 2018-03-19 2019-03-19 A novel form of ivermectin and a process for making it
US16/980,489 US20210023111A1 (en) 2018-03-19 2019-03-19 Novel Form of Invermectin and a Process for Making it
MX2020009669A MX2020009669A (es) 2018-03-19 2019-03-19 Una forma novedosa de ivermectina y un procedimiento para su produccion.
KR1020207029772A KR20200135417A (ko) 2018-03-19 2019-03-19 신규 형태의 이버멕틴 및 이의 제조방법
BR112020019214-7A BR112020019214A2 (pt) 2018-03-19 2019-03-19 Forma inovadora de ivermectina e processo para fazê-la
EP19714723.4A EP3768683A1 (en) 2018-03-19 2019-03-19 A novel form of ivermectin and a process for making it
PCT/GB2019/050760 WO2019180417A1 (en) 2018-03-19 2019-03-19 A novel form of ivermectin and a process for making it
JP2020550864A JP2021518416A (ja) 2018-03-19 2019-03-19 イベルメクチンの新規な形態及びその作成プロセス
IL277227A IL277227A (en) 2018-03-19 2020-09-08 A new form of ivermectin and a process for its preparation
JP2024067506A JP2024083612A (ja) 2018-03-19 2024-04-18 イベルメクチンの新規な形態及びその作成プロセス

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT110634A PT110634B (pt) 2018-03-19 2018-03-19 Ivermectina amorfa e processo para a sua produção

Publications (2)

Publication Number Publication Date
PT110634A true PT110634A (pt) 2019-09-19
PT110634B PT110634B (pt) 2021-03-17

Family

ID=65995772

Family Applications (1)

Application Number Title Priority Date Filing Date
PT110634A PT110634B (pt) 2018-03-19 2018-03-19 Ivermectina amorfa e processo para a sua produção

Country Status (12)

Country Link
US (1) US20210023111A1 (pt)
EP (1) EP3768683A1 (pt)
JP (2) JP2021518416A (pt)
KR (1) KR20200135417A (pt)
CN (1) CN111902416A (pt)
AU (1) AU2019237276B2 (pt)
BR (1) BR112020019214A2 (pt)
CA (1) CA3094448A1 (pt)
IL (1) IL277227A (pt)
MX (1) MX2020009669A (pt)
PT (1) PT110634B (pt)
WO (1) WO2019180417A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241307A1 (en) * 2021-02-04 2022-08-04 Hovione Scientia Limited Inhaled ivermectin
PT117268B (pt) 2021-06-01 2023-12-05 Hovione Farm S A Processo para controlar o tamanho de partícula e substâncias aparentadas da ivermectina com utilização de alto cisalhamento
WO2023003003A1 (ja) * 2021-07-20 2023-01-26 興和株式会社 新規吸入剤
CN116236448A (zh) * 2023-03-07 2023-06-09 四川新益峰生物制药有限公司 一种高效的阿苯达唑伊维菌素预混剂分散体颗粒组方与生产工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
NZ197796A (en) 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
US6265571B1 (en) 1999-07-12 2001-07-24 Magellan Laboratories, Inc. Purification process for anti-parasitic fermentation product
US8313774B1 (en) * 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas

Also Published As

Publication number Publication date
JP2024083612A (ja) 2024-06-21
PT110634B (pt) 2021-03-17
MX2020009669A (es) 2020-12-07
US20210023111A1 (en) 2021-01-28
CN111902416A (zh) 2020-11-06
IL277227A (en) 2020-10-29
RU2020134019A (ru) 2022-04-19
WO2019180417A1 (en) 2019-09-26
RU2020134019A3 (pt) 2022-04-19
CA3094448A1 (en) 2019-09-26
JP2021518416A (ja) 2021-08-02
BR112020019214A2 (pt) 2021-01-05
AU2019237276A1 (en) 2020-11-05
KR20200135417A (ko) 2020-12-02
EP3768683A1 (en) 2021-01-27
AU2019237276B2 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
PT110634A (pt) Ivermectina amorfa e processo para a sua produção
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112014024833A8 (pt) Produto farmacêutico veterinário mastigável macio, processo para a fabricação de um produto, uso de ácido pamóico ou um sal farmaceuticamente aceitável do mesmo, uso de um produto farmacêutico veterinário mastigável macio, e, composição farmacêutica veterinária mastigável macia.
PE20191492A1 (es) Composicion farmaceutica que comprende selexipag
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral
CO2021004131A2 (es) Formulación antibiótica inyectable de liberación sostenida
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
Kern Antibiotika und chemotherapeutika
Hamel et al. Treatment and control of bovine sarcoptic and psoroptic mange infestation with ivermectin long-acting injectable (IVOMEC® GOLD)
BR112015020443A2 (pt) desamorfização de formulações secadas por atomização via mistura por atomização
MX2021009877A (es) Extracto liquido de cera aleda, su formulacion y uso del mismo.
MX2018005596A (es) Vacuna para tratamiento y control de patologias infecciosas que usan heparan sulfato (hs) como receptor celular.
WO2020216283A1 (zh) 红色诺卡氏菌细胞壁骨架在治疗热损伤中的用途
BR112022010340A2 (pt) Composições farmacêuticas
DOP2023000171A (es) Formas de dosificación farmacéuticas que comprenden (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluorometil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
RU2523551C1 (ru) Мазь для лечения ожогов
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
BR112022004836A2 (pt) Processo para preparar um hidrogel super poroso plastificado, uso de um ou mais hidrogéis super porosos plastificados e formulação de dosagem oral
RU2592236C1 (ru) Способ лечения и профилактики нематодозов овец
Kern Antibiotika und antibakterielle Chemotherapeutika
BR112019028088A8 (pt) Dispersão sólida amorfa de belinostate, processo de preparação da dispersão sólida amorfa de belinostate e composição farmacêutica
HRP20170897A2 (hr) Topikalna farmaceutska formulacija na bazi mupirocina kao antivirusno sredstvo
BR112021026839A2 (pt) Composições farmacêuticas para tratar e para prevenir uma doença infecciosa do vírus influenza

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20190808

FG3A Patent granted, date of granting

Effective date: 20210312